MiMedx Group, Inc. MDXG

MDXG Company Overview

MiMedx Group, Inc. is a U.S.-based biopharmaceutical company that develops, manufactures, and markets placental tissue–based biologic products primarily used in advanced wound care and surgical applications. The company operates within the regenerative medicine and biologics segments of the healthcare industry, focusing on products derived from human placental tissues such as amniotic membrane and umbilical cord.

The company’s core revenue drivers are its biologic graft products used for chronic and acute wound treatment and for soft tissue healing in surgical settings. MiMedx serves hospitals, outpatient wound care centers, physician offices, and surgical centers, primarily in the United States. Its strategic positioning is based on proprietary processing technologies, a vertically integrated placental tissue supply chain, and a portfolio of products regulated under FDA human cell, tissue, and cellular and tissue-based product (HCT/P) frameworks. Founded in 2008, MiMedx evolved from an early-stage regenerative medicine developer into a commercial-stage biologics company following regulatory, governance, and operational restructuring in the early 2020s.